Compare BCTX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCTX | LSTA |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 16.4M |
| IPO Year | N/A | N/A |
| Metric | BCTX | LSTA |
|---|---|---|
| Price | $4.33 | $4.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $40.00 | $15.00 |
| AVG Volume (30 Days) | ★ 858.8K | 310.7K |
| Earning Date | 03-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $380.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.10 | $1.81 |
| 52 Week High | $98.20 | $4.17 |
| Indicator | BCTX | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 88.67 |
| Support Level | $4.10 | $2.05 |
| Resistance Level | $4.56 | $4.17 |
| Average True Range (ATR) | 0.71 | 0.15 |
| MACD | -0.25 | 0.25 |
| Stochastic Oscillator | 3.12 | 97.17 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.